Network pharmacology-based investigation and experimental validation of the mechanism of metformin in the treatment of acute myeloid leukemia

Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia. However, the detailed mechanisms by which metformin influences acute myeloid leukemia remain unrevealed. Employing a synergistic approach of...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of medical research Vol. 29; no. 1; pp. 475 - 12
Main Authors Liu, Shaoyu, Xu, Mingming, Yang, Zhuofan, Li, Yangzi, Wu, Depei, Tang, Xiaowen
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 30.09.2024
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia. However, the detailed mechanisms by which metformin influences acute myeloid leukemia remain unrevealed. Employing a synergistic approach of network pharmacology and experimental validation, this study systematically identifies and analyzes potential metformin targets and AML-related genes. These findings are then cross-referenced with biomedical databases to construct a target-gene network, providing insights into metformin's pharmacodynamics in AML treatment. Protein-Protein Interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses are utilized. Results show metformin's effectiveness in inhibiting AML cell proliferation and inducing apoptosis through the AKT/HIF1A/PDK1 signaling pathway. This research provides insights into metformin's clinical application in AML treatment.
AbstractList Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia. However, the detailed mechanisms by which metformin influences acute myeloid leukemia remain unrevealed. Employing a synergistic approach of network pharmacology and experimental validation, this study systematically identifies and analyzes potential metformin targets and AML-related genes. These findings are then cross-referenced with biomedical databases to construct a target-gene network, providing insights into metformin's pharmacodynamics in AML treatment. Protein-Protein Interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses are utilized. Results show metformin's effectiveness in inhibiting AML cell proliferation and inducing apoptosis through the AKT/HIF1A/PDK1 signaling pathway. This research provides insights into metformin's clinical application in AML treatment.Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia. However, the detailed mechanisms by which metformin influences acute myeloid leukemia remain unrevealed. Employing a synergistic approach of network pharmacology and experimental validation, this study systematically identifies and analyzes potential metformin targets and AML-related genes. These findings are then cross-referenced with biomedical databases to construct a target-gene network, providing insights into metformin's pharmacodynamics in AML treatment. Protein-Protein Interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses are utilized. Results show metformin's effectiveness in inhibiting AML cell proliferation and inducing apoptosis through the AKT/HIF1A/PDK1 signaling pathway. This research provides insights into metformin's clinical application in AML treatment.
Abstract Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia. However, the detailed mechanisms by which metformin influences acute myeloid leukemia remain unrevealed. Employing a synergistic approach of network pharmacology and experimental validation, this study systematically identifies and analyzes potential metformin targets and AML-related genes. These findings are then cross-referenced with biomedical databases to construct a target-gene network, providing insights into metformin's pharmacodynamics in AML treatment. Protein–Protein Interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses are utilized. Results show metformin's effectiveness in inhibiting AML cell proliferation and inducing apoptosis through the AKT/HIF1A/PDK1 signaling pathway. This research provides insights into metformin's clinical application in AML treatment.
Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia. However, the detailed mechanisms by which metformin influences acute myeloid leukemia remain unrevealed. Employing a synergistic approach of network pharmacology and experimental validation, this study systematically identifies and analyzes potential metformin targets and AML-related genes. These findings are then cross-referenced with biomedical databases to construct a target-gene network, providing insights into metformin's pharmacodynamics in AML treatment. Protein-Protein Interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses are utilized. Results show metformin's effectiveness in inhibiting AML cell proliferation and inducing apoptosis through the AKT/HIF1A/PDK1 signaling pathway. This research provides insights into metformin's clinical application in AML treatment.
Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia. However, the detailed mechanisms by which metformin influences acute myeloid leukemia remain unrevealed. Employing a synergistic approach of network pharmacology and experimental validation, this study systematically identifies and analyzes potential metformin targets and AML-related genes. These findings are then cross-referenced with biomedical databases to construct a target-gene network, providing insights into metformin's pharmacodynamics in AML treatment. Protein-Protein Interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses are utilized. Results show metformin's effectiveness in inhibiting AML cell proliferation and inducing apoptosis through the AKT/HIF1A/PDK1 signaling pathway. This research provides insights into metformin's clinical application in AML treatment. Keywords: Network pharmacology, Metformin, AML, Apoptosis, HIF1A
ArticleNumber 475
Audience Academic
Author Yang, Zhuofan
Tang, Xiaowen
Xu, Mingming
Liu, Shaoyu
Li, Yangzi
Wu, Depei
Author_xml – sequence: 1
  givenname: Shaoyu
  surname: Liu
  fullname: Liu, Shaoyu
– sequence: 2
  givenname: Mingming
  surname: Xu
  fullname: Xu, Mingming
– sequence: 3
  givenname: Zhuofan
  surname: Yang
  fullname: Yang, Zhuofan
– sequence: 4
  givenname: Yangzi
  surname: Li
  fullname: Li, Yangzi
– sequence: 5
  givenname: Depei
  surname: Wu
  fullname: Wu, Depei
– sequence: 6
  givenname: Xiaowen
  surname: Tang
  fullname: Tang, Xiaowen
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39343915$$D View this record in MEDLINE/PubMed
BookMark eNptkt1u1DAQhSNUREvpC3CBIiEhblLs2Pm7QlXFT6UKbkDizprY4123TrzYzsL2HXhnnE2puhKKolgz35z42Od5djS6EbPsJSXnlLb1u8AJIbQgJU8vKcvi7kl2UhLeFE3Lfhw9Wh9nZyHcJJrUZd103bPsmHWMs45WJ9mfLxh_OX-bb9bgB5DOutWu6CGgys24xRDNCqJxYw6jyvH3Br0ZcIxg8y1Yo5ae03lcYz6gXMNowjAXBoza-cGMSWffjR4hzrNzF-QU08AOrTMqtzjd4mDgRfZUgw14dv89zb5__PDt8nNx_fXT1eXFdSEr2saiJFBD2TKlUZeMdZpBi5xLVFRxxLLSjWy5Yih7BZRUDae6gapu-lbLhvfsNLtadJWDG7FJlsDvhAMj9gXnVwJ8NNKigKbnnNYKmeo5aOyaSgNCVdac97pXSev9orWZ-gGVTAY92APRw85o1mLltoJSzkld1Unh7b2Cdz-ndORiMEGitTCim4JglNJ0xenPCX29oCtIezOjdklSzri4aJPTtkv7StT5f6j0qHTIMuVIm1Q_GHjzaGCNYOM6ODvNlxsOwVePzT64_BeoBJQLIL0LwaN-QCgRc3DFElyRgiv2wRV37C9nT-PX
Cites_doi 10.1016/j.tips.2021.11.004
10.1001/jama.2019.3805
10.3390/ijms21082907
10.1016/j.gene.2019.02.076
10.3390/biom13020250
10.3389/fphar.2022.952677
10.1186/s13045-021-01062-w
10.1136/bmj.n2026
10.1186/s12943-023-01827-6
10.1016/j.metabol.2022.155223
10.1080/10428194.2017.1330956
10.1186/s13045-023-01424-6
10.1093/nar/gkz382
10.1016/j.redox.2019.101197
10.1016/j.gene.2017.06.035
10.3390/curroncol29090491
10.1016/j.gene.2021.145796
10.1002/ajh.26822
10.1038/nchembio.118
10.1111/cbdd.13860
10.1093/nar/gkw937
10.3389/fendo.2020.00191
ContentType Journal Article
Copyright 2024. The Author(s).
COPYRIGHT 2024 BioMed Central Ltd.
The Author(s) 2024 2024
Copyright_xml – notice: 2024. The Author(s).
– notice: COPYRIGHT 2024 BioMed Central Ltd.
– notice: The Author(s) 2024 2024
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1186/s40001-024-02022-z
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic





MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2047-783X
EndPage 12
ExternalDocumentID oai_doaj_org_article_a7b4416de3db4afe975faea52644bfbd
PMC11440656
A810589264
39343915
10_1186_s40001_024_02022_z
Genre Journal Article
GrantInformation_xml – fundername: Frontier Clinical Technical Project of Suzhou Science and Technology plan
  grantid: (SKY2022001)
– fundername: the Priority Academic Program Development of Jiangsu Higher Education Institutions
  grantid: (PAPD)
– fundername: Bethune Charitable Foundation
  grantid: (BCF-IBW-XY-20220930-13)
– fundername: Natural Science Foundation of Jiangsu Province
  grantid: (BK20201169)
– fundername: National Natural Science Foundation of China
  grantid: 81873443
– fundername: Suzhou diagnosis and treatment project of Clinical Key Diseases
  grantid: (LCZX202201)
– fundername: The Key Science Research Project of Jiangsu Commission of Health
  grantid: (K2019022)
– fundername: National Natural Science Foundation of China
  grantid: 82070162
– fundername: Translational Research Grant of NCRCH
  grantid: (2020ZKZC04)
GroupedDBID ---
0R~
4.4
53G
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABUWG
ACGFS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
DIK
EBD
EBLON
EBS
EMOBN
F5P
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
UKHRP
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c518t-20a6a283dfef2339f3a8e44ced1d4ee25f7c84d3ecbda105741f7a567b8fc74b3
IEDL.DBID M48
ISSN 2047-783X
0949-2321
IngestDate Wed Aug 27 01:16:12 EDT 2025
Thu Aug 21 18:31:07 EDT 2025
Fri Jul 11 15:57:36 EDT 2025
Tue Jun 17 22:03:19 EDT 2025
Tue Jun 10 20:58:21 EDT 2025
Thu May 22 21:25:17 EDT 2025
Mon Jul 21 05:40:29 EDT 2025
Tue Jul 01 02:25:22 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords AML
Network pharmacology
Metformin
HIF1A
Apoptosis
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c518t-20a6a283dfef2339f3a8e44ced1d4ee25f7c84d3ecbda105741f7a567b8fc74b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s40001-024-02022-z
PMID 39343915
PQID 3111202975
PQPubID 23479
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_a7b4416de3db4afe975faea52644bfbd
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11440656
proquest_miscellaneous_3111202975
gale_infotracmisc_A810589264
gale_infotracacademiconefile_A810589264
gale_healthsolutions_A810589264
pubmed_primary_39343915
crossref_primary_10_1186_s40001_024_02022_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-09-30
PublicationDateYYYYMMDD 2024-09-30
PublicationDate_xml – month: 09
  year: 2024
  text: 2024-09-30
  day: 30
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle European journal of medical research
PublicationTitleAlternate Eur J Med Res
PublicationYear 2024
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References Z Huang (2022_CR10) 2022
JA Webster (2022_CR2) 2018; 59
LF Newell (2022_CR5) 2021; 375
KK Gundapaneni (2022_CR23) 2017; 5
RJ Stubbins (2022_CR3) 2022; 29
P Yadav (2022_CR22) 2021; 98
S Shimony (2022_CR1) 2023; 98
AL Hopkins (2022_CR17) 2008; 4
RS Bhansali (2022_CR15) 2023; 16
C Nogales (2022_CR9) 2022; 43
J Flory (2022_CR6) 2019; 321
M Rashid (2022_CR20) 2021; 798
A Daina (2022_CR11) 2019; 47
A Glaviano (2022_CR13) 2023; 22
T Liu (2022_CR21) 2019; 25
E Minet (2022_CR14) 2000; 5
S Noorolyai (2022_CR19) 2019; 25
CR Triggle (2022_CR16) 2022; 133
YZ Fang (2022_CR8) 2023; 13
I Nepstad (2022_CR18) 2020; 21
H Liu (2022_CR4) 2021; 14
Z Lv (2022_CR7) 2020; 11
D Szklarczyk (2022_CR12) 2017; 45
References_xml – volume: 43
  start-page: 136
  issue: 2
  year: 2022
  ident: 2022_CR9
  publication-title: Trends Pharmacol Sci.
  doi: 10.1016/j.tips.2021.11.004
– volume: 321
  start-page: 1926
  issue: 19
  year: 2019
  ident: 2022_CR6
  publication-title: JAMA
  doi: 10.1001/jama.2019.3805
– volume: 21
  start-page: 2907
  issue: 8
  year: 2020
  ident: 2022_CR18
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms21082907
– volume: 25
  start-page: 120
  issue: 698
  year: 2019
  ident: 2022_CR19
  publication-title: Gene
  doi: 10.1016/j.gene.2019.02.076
– volume: 13
  start-page: 250
  year: 2023
  ident: 2022_CR8
  publication-title: Biomolecules
  doi: 10.3390/biom13020250
– year: 2022
  ident: 2022_CR10
  publication-title: Front Pharmacol.
  doi: 10.3389/fphar.2022.952677
– volume: 14
  start-page: 49
  year: 2021
  ident: 2022_CR4
  publication-title: J Hematol Oncol.
  doi: 10.1186/s13045-021-01062-w
– volume: 375
  year: 2021
  ident: 2022_CR5
  publication-title: BMJ
  doi: 10.1136/bmj.n2026
– volume: 22
  start-page: 138
  issue: 1
  year: 2023
  ident: 2022_CR13
  publication-title: Mol Cancer
  doi: 10.1186/s12943-023-01827-6
– volume: 133
  year: 2022
  ident: 2022_CR16
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2022.155223
– volume: 59
  start-page: 274
  issue: 2
  year: 2018
  ident: 2022_CR2
  publication-title: Leuk Lymphoma.
  doi: 10.1080/10428194.2017.1330956
– volume: 16
  start-page: 29
  issue: 1
  year: 2023
  ident: 2022_CR15
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-023-01424-6
– volume: 47
  start-page: W357
  issue: W1
  year: 2019
  ident: 2022_CR11
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkz382
– volume: 25
  year: 2019
  ident: 2022_CR21
  publication-title: Redox Biol
  doi: 10.1016/j.redox.2019.101197
– volume: 5
  start-page: 253
  issue: 3
  year: 2000
  ident: 2022_CR14
  publication-title: Int J Mol Med
– volume: 5
  start-page: 278
  issue: 627
  year: 2017
  ident: 2022_CR23
  publication-title: Gene
  doi: 10.1016/j.gene.2017.06.035
– volume: 29
  start-page: 6245
  issue: 9
  year: 2022
  ident: 2022_CR3
  publication-title: Curr Oncol
  doi: 10.3390/curroncol29090491
– volume: 798
  year: 2021
  ident: 2022_CR20
  publication-title: Gene
  doi: 10.1016/j.gene.2021.145796
– volume: 98
  start-page: 502
  year: 2023
  ident: 2022_CR1
  publication-title: Am J Hematol
  doi: 10.1002/ajh.26822
– volume: 4
  start-page: 682
  issue: 11
  year: 2008
  ident: 2022_CR17
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio.118
– volume: 98
  start-page: 144
  issue: 1
  year: 2021
  ident: 2022_CR22
  publication-title: Chem Biol Drug Des
  doi: 10.1111/cbdd.13860
– volume: 45
  start-page: D362
  issue: D1
  year: 2017
  ident: 2022_CR12
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkw937
– volume: 11
  start-page: 191
  year: 2020
  ident: 2022_CR7
  publication-title: Front Endocrinol
  doi: 10.3389/fendo.2020.00191
SSID ssj0000626799
Score 2.36626
Snippet Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia....
Abstract Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 475
SubjectTerms AML
Apoptosis
Apoptosis - drug effects
Cancer
Care and treatment
Cell Proliferation - drug effects
Diabetes therapy
Drug therapy
Gene Regulatory Networks - drug effects
Genes
Genomes
Genomics
HIF1A
Humans
Hypoxia-Inducible Factor 1, alpha Subunit - genetics
Hypoxia-Inducible Factor 1, alpha Subunit - metabolism
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - metabolism
Leukemia, Myeloid, Acute - pathology
Metformin
Metformin - pharmacology
Metformin - therapeutic use
Network pharmacology
Network Pharmacology - methods
Pharmacology
Protein Interaction Maps - drug effects
Protein-protein interactions
Proto-Oncogene Proteins c-akt - metabolism
Signal Transduction - drug effects
Type 2 diabetes
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k2gBSMhcUBRSew4ybEgqgqpPVGpN8uPsYjoJlU3e2j_A_-5M3Z2m4gDFw57yUyitWfG30SZ-Yaxj0GUQDxleXAgcymDza0qmlwgvAjwra8U9Q6fnqmTc_njorqYjfqimrBED5w27tDUFhFbeRDeShOgratgwFQE5DZYT6cvYt7sZSqdwaWq23bbJdOow7X8EquHSok_KmG_XSBRJOz_-1ie4dKyZnIGQsdP2OMpe-RH6V8_ZQ-gf8Yenk7fx5-zP2epqptf3TNS3-SEVJ5394waQ89N7_mc3Z-jx3VpvhIfAse0kK-AuoK79YourGCk9Lbr8TlRuqtQJ6lxmxFvuIHLofP8Eja_YdWZF-z8-PvPbyf5NHAhd1XRjBgxRhnMN3yAUArRBmEakNKBL7wEKKtQu0Z6Ac56QwOCZRFqU6naNsHV0oqXbK8fenjNuAVMpkKL-Z0RMgjVOgMVEPmirIMqy4x93m6-vkq8Gjq-jzRKJ1NpNJWOptK3GftK9tlpEid2vICeoidP0f_ylIy9J-vq1GC6i2x91BQ0WxHVMvYpalBso5GdmVoUcEnEkrXQ3F9oYky6hfjD1oM0iaiQrYdhs9YCsaWkgWFVxl4lj9qtSrSC-qBR0ix8bbHspaTvfkVK8IK-0WNq_uZ_bNRb9qiMcUJVMftsb7zewAGmXqN9F6PsDqMVMVw
  priority: 102
  providerName: Directory of Open Access Journals
Title Network pharmacology-based investigation and experimental validation of the mechanism of metformin in the treatment of acute myeloid leukemia
URI https://www.ncbi.nlm.nih.gov/pubmed/39343915
https://www.proquest.com/docview/3111202975
https://pubmed.ncbi.nlm.nih.gov/PMC11440656
https://doaj.org/article/a7b4416de3db4afe975faea52644bfbd
Volume 29
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3di9NAEF_uA8QX8dvqWSMIPkjUZDfZ5EGkJ3cchRZRC31bdrOzGmyTsx9g73_wf3Zmk_YaPPAhBDKTwGZmMr8kM79h7JXjMRBPWegKEKEQzoQmjbKQY3rhYHObpNQ7PBqnFxMxnCbTA7Ydd9TewOWNr3Y0T2qymL39_WvzEQP-gw_4LH23FO99YVAscKPq9KtDdoyZSdJEg1EL95snc5zKvKHfE3mIYCLa9tHceJlOrvKU_v8-uPcyV7eqci9Nnd9ld1p8GQwah7jHDqC6z26N2j_oD9ifcVP3HVxec1ZvQsplNiivOTfqKtCVDfb5_wP0ybKZwBTULkDgGMyB-obL5ZwOzGFFALis8DpeuqthJ6ku1is8YQOzurTBDNY_YV7qh2xyfvbt00XYjmQIiyTKVhhTOtWISKwDF3OeO64zEKIAG1kBECdOFpmwHApjNY0QFpGTOkmlyVwhheGP2FFVV_CEBQYQbrkcEaDmwvE0LzQkQPSMQro0jnvszfbmq8uGeUP5N5YsVY2pFJpKeVOpqx47JfvsNIk12x-oF99VG4RKS4PoL7XArRHaQS4Tp0EnBAqNM7bHXpB1VdOCuot9Ncgimr6Iaj322muQP6KRC902MeCSiEero3nS0cSoLTril1sPUiSiUrcK6vVSccw-MY0US3rsceNRu1XxnFOnNEqyjq91lt2VVOUPTxoe0V98BO9P_7vGZ-x27IOAimJO2NFqsYbniLxWps8O5VT22fFgMPw6xP3p2fjzl77_jtH3ofYXmYQyQA
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Network+pharmacology-based+investigation+and+experimental+validation+of+the+mechanism+of+metformin+in+the+treatment+of+acute+myeloid+leukemia&rft.jtitle=European+journal+of+medical+research&rft.au=Yang%2C+Zhuofan&rft.au=Tang%2C+Xiaowen&rft.au=Xu%2C+Mingming&rft.au=Li%2C+Yangzi&rft.date=2024-09-30&rft.pub=BioMed+Central+Ltd&rft.issn=0949-2321&rft.volume=29&rft.issue=1&rft_id=info:doi/10.1186%2Fs40001-024-02022-z&rft.externalDBID=n%2Fa&rft.externalDocID=A810589264
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-783X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-783X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-783X&client=summon